Next Steps for the Pneumococcal Vaccines Work Group

Miwako Kobayashi, MD, MPH
Pneumococcal Vaccines Work Group
Advisory Committee on Immunization Practices
February 24, 2022
Policy Questions Being Considered by the Work Group

- Should PCV15 be routinely recommended for U.S. children <2 years of age as an option for pneumococcal conjugate vaccination according to currently recommended dosing and schedules?

- Should PCV15 be recommended for U.S. children with underlying medical conditions 2–18 years of age as an option for pneumococcal conjugate vaccination according to currently recommended dosing and schedules?

Pneumococcal Conjugate Vaccine Options

PCV13  OR  PCV15
Evidence Reviewed by the Work Group

• Epidemiology of pneumococcal disease and vaccine-preventable disease burden for:
  • Invasive pneumococcal disease
  • Pneumonia
  • Acute otitis media

• Immunogenicity and safety of PCV15 in children (Phase 2/3 studies)

• GRADE and EtR
  • Public Health Problem, Benefits and Harms, Values, Equity
Evidence to be Reviewed by the Work Group

• Epidemiology of pneumococcal disease and vaccine-preventable disease burden for:
  • Invasive pneumococcal disease
  • Pneumonia
  • Acute otitis media

• Immunogenicity and safety of PCV15 in children (Phase 2/3 studies)

• GRADE and EtR
  • Public Health Problem, Benefits and Harms, Values, Equity
  • Resource Use (Cost-effective analysis), Acceptability, Feasibility
Proposed Timeline of ACIP Presentations (Tentative)

Feb 2022 ACIP

Presentation on:
• Pediatric Pneumococcal disease epi
• Phase 2/3 PCV15 studies in children
• EtR (part 1)/GRADE

→

June ‘22 ACIP

Presentation on:
• Cost-effectiveness analysis
• EtR (part 2)

Vote (if product licensed for use)
Questions for the Committee

- Does the Committee agree with the policy questions being considered by the Work Group?
- Are there additional data the Committee would like to see before deciding on policy options for a vote?
Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.